Your shopping cart is currently empty

LDHA-IN-3 (1-(phenylseleno)-4-(trifluoromethyl) benzene) is a potent non-competitive lactate dehydrogenase (LDHA) inhibitor with an IC50 value of 145.2 nM.LDHA-IN-3 is a selenobenzene compound that can be used in cancer research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $50 | In Stock | In Stock | |
| 5 mg | $122 | In Stock | In Stock | |
| 10 mg | $196 | In Stock | In Stock | |
| 25 mg | $413 | - | In Stock | |
| 50 mg | $575 | - | In Stock | |
| 100 mg | $786 | - | In Stock | |
| 200 mg | $1,080 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $133 | - | In Stock |
| Description | LDHA-IN-3 (1-(phenylseleno)-4-(trifluoromethyl) benzene) is a potent non-competitive lactate dehydrogenase (LDHA) inhibitor with an IC50 value of 145.2 nM.LDHA-IN-3 is a selenobenzene compound that can be used in cancer research. |
| Targets&IC50 | LDHA:145.2 nM (IC50) |
| In vitro | LDHA-IN-3 (PSTMB) (0~500 μM; 48 h; MCF-7 cells) has cytotoxic effects.[1] PSTMB (0.01~1 μM) has a dose-dependent inhibitory effect on LDHA activity. PSTMB (0~0.5 μM) inhibits LDHA activity in Michaelis-Menten and Lineweaver-Burk plots.[1] PSTMB (30 and 50 μM; HT29 cells) induces ROS production and mitochondrial damage.[1] PSTMB efficiently binds to LDHA protein. PSTMB induces intrinsic pathway-mediated apoptosis in cancer cells through the production of mitochondrial ROS.[1] |
| Synonyms | PSTMB, 1-(phenylseleno)-4-(trifluoromethyl) benzene |
| Molecular Weight | 301.17 |
| Formula | C13H9F3Se |
| Cas No. | 227010-33-5 |
| Smiles | [Se](C1=CC=C(C(F)(F)F)C=C1)C2=CC=CC=C2 |
| Relative Density. | no data available |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (199.22 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.64 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.